Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity

被引:2
|
作者
Chen, Jing [1 ]
Hao, Qingfei [1 ]
Zhang, Jing [1 ]
Du, Yanna [1 ]
Chen, Haoming [1 ]
Cheng, Xiuyong [1 ]
机构
[1] Zhengzhou Univ, Dept Neonatol, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2023年 / 10卷
关键词
body weight gain; intravitreal anti-VEGF; multiple systems; retinopathy of prematurity; ranibizumab; aflibercept; BEVACIZUMAB; HYPERTENSION; OUTCOMES; INFANTS; LASER; RANIBIZUMAB; AFLIBERCEPT; INJECTION; EFFICACY; VEGF;
D O I
10.3389/fped.2022.1077137
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
ObjectivesThis study's goal was to assess the short-term effect on body weight and multiple systems following intravitreal injections of ranibizumab and aflibercept for retinopathy of prematurity (ROP). MethodsWe retrospectively assessed infants with ROP who received intravitreal anti-vascular endothelial growth factor agents (VEGF) treatment at our hospital. They were classified into 2 groups based on the drugs administered: the intravitreal ranibizumab (IVR) group and the intravitreal aflibercept (IVA) group. The body weight (BW) gains for the pre-treatment week, the 1st week after treatment, and the 2nd week after treatment were compared for each group. Additionally, other parameters such as blood pressure, heart rate, oxygen concentration, volume of milk and output of urine at four time points were also measured. We used repeated measurement analysis of variance analyzed these data. ResultsIn total, 95 preterm infants were recruited, including 51 cases in the IVR group and 44 cases in the IVA group. The BW gain for the 1st week after treatment was significantly lower than the pre-treatment week in each group (P < 0.05), while there was no decrease in weekly BW gain in the 2nd week after treatment compared with that pre-treatment week. Based on the comparison between groups, the BW gain in the IVR group was significantly higher than in the IVA group in the second post-treatment week. Repeated measurement analysis of variance showed that there were no significant differences in blood pressure, heart rate, oxygen concentration, volume of milk and output of urine in both groups over time. ConclusionsIVR and IVA could have a short-term inhibitive effect on body weight gain in infants after treatment for ROP, whereas there is no significant impact on other systems.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Editorial to: visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity
    Kozak, Igor
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 261 (11) : 3049 - 3049
  • [22] Editorial to: visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity
    Igor Kozak
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 3049 - 3049
  • [23] Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
    Taher, Nada O.
    Ghaddaf, Abdullah A.
    Al-Ghamdi, Sarah A.
    Homsi, Jumanah J.
    Al-Harbi, Bandar J.
    Alomari, Lugean K.
    Almarzouki, Hashem S.
    FRONTIERS IN MEDICINE, 2022, 9
  • [24] How Does the Standard of Care Evolve? Anti-Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an Example
    Chiang, Michael F.
    OPHTHALMOLOGY, 2018, 125 (10) : 1485 - 1487
  • [25] Plasma levels of vascular endothelial growth factor and anti-vascular endothelial growth factor before and after intravitreal injection of anti-vascular endothelial growth factor
    Park, Sang Jun
    Yoon, Myung Hun
    Chung, Ah Reum
    Chin, Hee Seung
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [26] The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review
    Chow, Shing Chuen
    Lam, Pun Yuet
    Lam, Wai Ching
    Fung, Nicholas Siu Kay
    EYE, 2022, 36 (08) : 1532 - 1545
  • [27] Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity
    Darwish, Dana
    Chee, Ru-Ik
    Patel, Samir N.
    Jonas, Karyn
    Ostmo, Susan
    Campbell, J. Peter
    Chiang, Michael F.
    Chan, R. V. Paul
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2018, 7 (03): : 136 - 144
  • [28] REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY
    Cernichiaro-Espinosa, Linda A.
    Harper, Clio A., III
    Read, Sarah P.
    Wright, Lauren M.
    Scribbick, Frank W., III
    Young, Ryan
    Negron, Catherin I.
    Rodriguez, Ana
    Berrocal, Audina M.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (06): : 1251 - 1255
  • [29] Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents
    Labardini, Cecilia P.
    Blumenthal, Eytan Z.
    RAMBAM MAIMONIDES MEDICAL JOURNAL, 2018, 9 (04):
  • [30] Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis
    Xu, Yufei
    Deng, Guohua
    Zhang, Jun
    Zhu, Jie
    Liu, Zhinan
    Xu, Fan
    Zhou, Dong
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (04): : 676 - 687